<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34200812</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>10</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Diabetes Mellitus and Amyotrophic Lateral Sclerosis: A Systematic Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">867</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom11060867</ELocationID><Abstract><AbstractText Label="BACKGROUND">Amyotrophic Lateral Sclerosis (ALS) is a degenerative disorder which affects the motor neurons. Growing evidence suggests that ALS may impact the metabolic system, including the glucose metabolism. Several studies investigated the role of Diabetes Mellitus (DM) as risk and/or prognostic factor. However, a clear correlation between DM and ALS has not been defined. In this review, we focus on the role of DM in ALS, examining the different hypotheses on how perturbations of glucose metabolism may interact with the pathophysiology and the course of ALS.</AbstractText><AbstractText Label="METHODS">We undertook an independent PubMed literature search, using the following search terms: ((ALS) OR (Amyotrophic Lateral Sclerosis) OR (Motor Neuron Disease)) AND ((Diabetes) OR (Glucose Intolerance) OR (Hyperglycemia)). Review and original articles were considered.</AbstractText><AbstractText Label="RESULTS">DM appears not to affect ALS severity, progression, and survival. Contrasting data suggested a protective role of DM on the occurrence of ALS in elderly and an opposite effect in younger subjects.</AbstractText><AbstractText Label="CONCLUSIONS">The actual clinical and pathophysiological correlation between DM and ALS is unclear. Large longitudinal prospective studies are needed. Achieving large sample sizes comparable to those of common complex diseases like DM is a challenge for a rare disease like ALS. Collaborative efforts could overcome this specific issue.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferri</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2105-5038</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ajdinaj</LastName><ForeName>Paola</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8173-1723</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rispoli</LastName><ForeName>Marianna Gabriella</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0002-6709-3489</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrarini</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbone</LastName><ForeName>Filomena</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Ardes</LastName><ForeName>Damiano</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine and Aging Sciences, University G. d'Annunzio of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capasso</LastName><ForeName>Margherita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, "SS Annunziata" Hospital, 66100 Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muzio</LastName><ForeName>Antonio Di</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Neurology, "SS Annunziata" Hospital, 66100 Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cipollone</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine and Aging Sciences, University G. d'Annunzio of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onofrj</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonanni</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7443-9233</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, 66100 Chieti, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">comorbidities</Keyword><Keyword MajorTopicYN="N">diabetes mellitus</Keyword><Keyword MajorTopicYN="N">glucose intolerance</Keyword><Keyword MajorTopicYN="N">hyperglycemia</Keyword><Keyword MajorTopicYN="N">metabolism</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>2</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34200812</ArticleId><ArticleId IdType="pmc">PMC8230511</ArticleId><ArticleId IdType="doi">10.3390/biom11060867</ArticleId><ArticleId IdType="pii">biom11060867</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Chalabi A., Hardiman O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Moglia C., Canosa A., Manera U., D&#x2019;Ovidio F., Vasta R., Grassano M., Brunetti M., Barberis M., Corrado L., et al. ALS phenotype is influenced by age, sex, and genetics. Neurology. 2020;94:e802&#x2013;e810. doi: 10.1212/WNL.0000000000008869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008869</ArticleId><ArticleId IdType="pubmed">31907290</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R. CLINICAL EPIDEMIOLOGY OF AMYOTROPHIC LATERAL SCLEROSIS. Neurol. Clin. 1996;14:399&#x2013;420. doi: 10.1016/S0733-8619(05)70264-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0733-8619(05)70264-4</ArticleId><ArticleId IdType="pubmed">8827179</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R. Natural history of ALS: Symptoms, strength, pulmonary function, and disability. Neurology. 1996;47:71&#x2013;82. doi: 10.1212/WNL.47.4_Suppl_2.71S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.4_Suppl_2.71S</ArticleId><ArticleId IdType="pubmed">8858055</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadimitriou D., Le Verche V., Jacquier A., Ikiz B., Przedborski S., Re D.B. Inflammation in ALS and SMA: Sorting out the good from the evil. Neurobiol. Dis. 2010;37:493&#x2013;502. doi: 10.1016/j.nbd.2009.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.10.005</ArticleId><ArticleId IdType="pmc">PMC2823924</ArticleId><ArticleId IdType="pubmed">19833209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H., Polymenidou M., Cleveland D.W. Non&#x2013;cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009;187:761&#x2013;772. doi: 10.1083/jcb.200908164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200908164</ArticleId><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutini M., Frazzini V., Marini C., Spalloni A., Sensi S.L., Longone P. Zinc pre-treatment enhances NMDAR-mediated excitotoxicity in cultured cortical neurons from SOD1G93A mouse, a model of amyotrophic lateral sclerosis. Neuropharmacol. 2011;60:1200&#x2013;1208. doi: 10.1016/j.neuropharm.2010.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2010.11.001</ArticleId><ArticleId IdType="pubmed">21056589</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E.F., Shaw P.J., De Vos K.J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 2019;710:132933. doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodall E.F., Morrison K.E. Amyotrophic lateral sclerosis (motor neuron disease): Proposed mechanisms and pathways to treatment. Expert Rev. Mol. Med. 2006;8:1&#x2013;22. doi: 10.1017/S1462399406010854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1462399406010854</ArticleId><ArticleId IdType="pubmed">16723044</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K., Watanabe K., Yuki S., Akimoto M., Sakata T., Palumbo J. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2017;18:5&#x2013;10. doi: 10.1080/21678421.2017.1353101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1353101</ArticleId><ArticleId IdType="pubmed">28872907</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Pradat P.-F., Ludolph A.C., Loeffler J.-P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A., Khan R., Polymenidou M., Schulz P.E. Disease-modifying effects of metabolic perturbations in ALS/FTLD. Mol. Neurodegener. 2018;13:1&#x2013;16. doi: 10.1186/s13024-018-0294-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0294-0</ArticleId><ArticleId IdType="pmc">PMC6278047</ArticleId><ArticleId IdType="pubmed">30509290</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito M.D., Da Silva G.F.G., Tilieri E.M., Araujo B.G., Cali&#xf3; M.L., Rosenstock T.R. Metabolic Alteration and Amyotrophic Lateral Sclerosis Outcome: A Systematic Review. Front. Neurol. 2019;10:1205. doi: 10.3389/fneur.2019.01205.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.01205</ArticleId><ArticleId IdType="pmc">PMC6879457</ArticleId><ArticleId IdType="pubmed">31824397</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J.-C., Torny F., Lacoste M., Preux P.-M., Couratier P. Hypermetabolism in ALS: Correlations with Clinical and Paraclinical Parameters. Neurodegener. Dis. 2005;2:202&#x2013;207. doi: 10.1159/000089626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000089626</ArticleId><ArticleId IdType="pubmed">16909026</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouteloup C., Desport J.-C., Clavelou P., Guy N., Derumeaux-Burel H., Ferrier A., Couratier P. Hypermetabolism in ALS patients: An early and persistent phenomenon. J. Neurol. 2009;256:1236&#x2013;1242. doi: 10.1007/s00415-009-5100-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5100-z</ArticleId><ArticleId IdType="pubmed">19306035</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn F.J., Ioannides Z.A., Van Eijk R.P.A., Heggie S., Thorpe K.A., Ceslis A., Heshmat S., Henders A.K., Wray N.R., Berg L.H.V.D., et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J. Neurol. Neurosurg. Psychiatry. 2018;89:1016&#x2013;1023. doi: 10.1136/jnnp-2017-317887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317887</ArticleId><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S. Hypermetabolism appears to be an adverse prognostic biomarker in amyotrophic lateral sclerosis: A potential for therapeutic intervention? Eur. J. Neurol. 2017;25:1&#x2013;2. doi: 10.1111/ene.13470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13470</ArticleId><ArticleId IdType="pubmed">28940741</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J.C., Preux P.M., Magy L., Boirie Y., Vallat J.M., Beaufr&#xe8;re B., Couratier P. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am. J. Clin. Nutr. 2001;74:328&#x2013;334. doi: 10.1093/ajcn/74.3.328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/74.3.328</ArticleId><ArticleId IdType="pubmed">11522556</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergani A., Oudart H., De Aguilar J.-L.G., Fricker B., Ren&#xe9; F., Hocquette J.-F., Meininger V., Dupuis L., Loeffler J.-P. Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis. J. Lipid Res. 2007;48:1571&#x2013;1580. doi: 10.1194/jlr.M700017-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M700017-JLR200</ArticleId><ArticleId IdType="pmc">PMC1974855</ArticleId><ArticleId IdType="pubmed">17438338</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Oudart H., Rene F., de Aguilar J.-L.G., Loeffler J.-P. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model. Proc. Natl. Acad. Sci. USA. 2004;101:11159&#x2013;11164. doi: 10.1073/pnas.0402026101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402026101</ArticleId><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Corcia P., Fergani A., De Aguilar J.-L.G., Bonnefont-Rousselot D., Bittar R., Seilhean D., Hauw J.-J., Lacomblez L., Loeffler J.-P., et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004&#x2013;1009. doi: 10.1212/01.wnl.0000285080.70324.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Logroscino G., Hardiman O., Swingler R., Mitchell D., Beghi E., Traynor B.G. On Behalf of the Eurals Consortium Prognostic factors in ALS: A critical review. Amyotroph. Lateral Scler. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J.C., Preux P.M., Truong T.C., Vallat J.M., Sautereau D., Couratier P. Nutritional status is a prognostic factor for survival in ALS patients. Neurology. 1999;53:1059. doi: 10.1212/WNL.53.5.1059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.53.5.1059</ArticleId><ArticleId IdType="pubmed">10496266</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape J., Grose J. The effects of diet and sex in amyotrophic lateral sclerosis. Rev. Neurol. 2020;176:301&#x2013;315. doi: 10.1016/j.neurol.2019.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2019.09.008</ArticleId><ArticleId IdType="pubmed">32147204</ArticleId></ArticleIdList></Reference><Reference><Citation>Che&#x142;stowska B., Ku&#x17a;ma-Kozakiewicz M. Biochemical parameters in determination of nutritional status in amyotrophic lateral sclerosis. Neurol. Sci. 2020;41:1115&#x2013;1124. doi: 10.1007/s10072-019-04201-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04201-x</ArticleId><ArticleId IdType="pubmed">31897946</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A., Murthy S.B., Wilson A.M., Qureshi S.U., Amro M.J., Wheaton M., Simpson E., Harati Y., Strutt A.M., York M.K., et al. A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph. Lateral Scler. 2010;11:542&#x2013;548. doi: 10.3109/17482968.2010.482592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.482592</ArticleId><ArticleId IdType="pubmed">20500116</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat P.-F., Bruneteau G., Gordon P.H., Dupuis L., Bonnefont-Rousselot D., Simon D., Salachas F., Corcia P., Frochot V., Lacorte J.-M., et al. Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2010;11:166&#x2013;171. doi: 10.3109/17482960902822960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902822960</ArticleId><ArticleId IdType="pubmed">20184518</ArticleId></ArticleIdList></Reference><Reference><Citation>Harno K., Rissanen A., Palo J. Glucose tolerance in amyotrophic lateral sclerosis. Acta Neurol. Scand. 2009;70:451&#x2013;455. doi: 10.1111/j.1600-0404.1984.tb00851.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1984.tb00851.x</ArticleId><ArticleId IdType="pubmed">6516795</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes E.T., Perurena O.H., Festoff B.W., Jorgensen R., Moore W.V. Insulin resistance in amyotrophic lateral sclerosis. J. Neurol. Sci. 1984;63:317&#x2013;324. doi: 10.1016/0022-510X(84)90154-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(84)90154-0</ArticleId><ArticleId IdType="pubmed">6374040</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu T., Honda M., Ohashi T., Tsujino M., Nagaoka U., Kawata A., Watabe K., Matsubara S., Hayashi H. Hyperosmolar hyperglycemic state in advanced amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2010;12:379&#x2013;381. doi: 10.3109/17482968.2010.539234.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.539234</ArticleId><ArticleId IdType="pubmed">21126160</ArticleId></ArticleIdList></Reference><Reference><Citation>Lekoubou A., Matsha T.E., Sobngwi E., Kengne A.P. Effects of diabetes mellitus on amyotrophic lateral sclerosis: A systematic review. BMC Res. Notes. 2014;7:171. doi: 10.1186/1756-0500-7-171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-0500-7-171</ArticleId><ArticleId IdType="pmc">PMC3987838</ArticleId><ArticleId IdType="pubmed">24661645</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ovidio F., D&#x2019;Errico A., Carn&#xe0; P., Calvo A., Costa G., Chi&#xf2; A. The role of pre-morbid diabetes on developing amyotrophic lateral sclerosis. Eur. J. Neurol. 2017;25:164&#x2013;170. doi: 10.1111/ene.13465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13465</ArticleId><ArticleId IdType="pubmed">28921834</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A., Salamone A.R., Strutt A.M., Murthy S.B., Wheaton M., McDowell E.J., Simpson E., Appel S.H., York M.K., Schulz P.E. ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Eur. J. Neurol. 2010;17:733&#x2013;739. doi: 10.1111/j.1468-1331.2009.02923.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02923.x</ArticleId><ArticleId IdType="pubmed">20074230</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A., Schulz P.E. Pre-morbid type 2 diabetes mellitus as a prognostic factor in amyotrophic lateral sclerosis. Muscle Nerve. 2015;52:690&#x2013;691. doi: 10.1002/mus.24758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24758</ArticleId><ArticleId IdType="pubmed">26137991</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A., Brown J.A., Schulz P.E. Diabetes mellitus in amyotrophic lateral sclerosis: Dr. Jekyll or Mr. Hyde? Eur. J. Neurol. 2015;22:1419&#x2013;1420. doi: 10.1111/ene.12660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12660</ArticleId><ArticleId IdType="pubmed">25597340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou M.-A., Rotem R.S., Seals R.M., Gredal O., Hansen J., Weisskopf M.G. Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis. JAMA Neurol. 2015;72:905&#x2013;911. doi: 10.1001/jamaneurol.2015.0910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.0910</ArticleId><ArticleId IdType="pmc">PMC4975611</ArticleId><ArticleId IdType="pubmed">26030836</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G. Are diabetes and amyotrophic lateral sclerosis related? Nat. Rev. Neurol. 2015;11:488&#x2013;490. doi: 10.1038/nrneurol.2015.145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.145</ArticleId><ArticleId IdType="pubmed">26281962</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D., Kamel F., Bellocco R., Ye W., Fang F. Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur. J. Neurol. 2015;22:1436&#x2013;1442. doi: 10.1111/ene.12632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12632</ArticleId><ArticleId IdType="pmc">PMC4506907</ArticleId><ArticleId IdType="pubmed">25600257</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D., Kamel F., Bellocco R., Ronnevi L., Almqvist C., Larsson H., Ye W., Fang F. Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur. J. Neurol. 2020;27:1010&#x2013;1016. doi: 10.1111/ene.14190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14190</ArticleId><ArticleId IdType="pubmed">32097525</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C., Calvo A., Canosa A., Bertuzzo D., Cugnasco P., Solero L., Grassano M., Bersano E., Cammarosano S., Manera U., et al. Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: A population-based study. Amyotroph. Lateral Scler. Front. Degener. 2017;18:590&#x2013;597. doi: 10.1080/21678421.2017.1336560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1336560</ArticleId><ArticleId IdType="pubmed">28616937</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Bs T.H., Shui A., Allred P., Harms M., Liu J., Maragakis N., Schoenfeld D., Yu H., Atassi N., et al. Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Muscle Nerve. 2015;52:339&#x2013;343. doi: 10.1002/mus.24688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24688</ArticleId><ArticleId IdType="pmc">PMC4536144</ArticleId><ArticleId IdType="pubmed">25900666</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Chen L., Fan D. The protective role of pre-morbid type 2 diabetes in patients with amyotrophic lateral sclerosis: A center-based survey in China. Amyotroph. Lateral Scler. Front. Degener. 2019;21:209&#x2013;215. doi: 10.1080/21678421.2019.1704010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1704010</ArticleId><ArticleId IdType="pubmed">31852260</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Lu C.-J., Chen R.-C., Hou W.-H., Li C.-Y. Risk of Amyotrophic Lateral Sclerosis in Patients With Diabetes: A Nationwide Population-Based Cohort Study. J. Epidemiol. 2015;25:445&#x2013;451. doi: 10.2188/jea.JE20140176.</Citation><ArticleIdList><ArticleId IdType="doi">10.2188/jea.JE20140176</ArticleId><ArticleId IdType="pmc">PMC4444499</ArticleId><ArticleId IdType="pubmed">25947580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P., Wang T., Zheng J., Zhou X. Causal association of type 2 diabetes with amyotrophic lateral sclerosis: New evidence from Mendelian randomization using GWAS summary statistics. BMC Med. 2019;17:1&#x2013;13. doi: 10.1186/s12916-019-1448-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-019-1448-9</ArticleId><ArticleId IdType="pmc">PMC6892209</ArticleId><ArticleId IdType="pubmed">31796040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J., Ferri L., Fasano A., Zucchi E., Fini N., Moglia C., Lunetta C., Marinou K., Ticozzi N., Ferrante G.D., et al. Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. Eur. J. Neurol. 2018;25:861&#x2013;868. doi: 10.1111/ene.13620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13620</ArticleId><ArticleId IdType="pubmed">29512869</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J., ERRALS Group. Malerba S.A., Beghi E., Fini N., Fasano A., Zucchi E., De Pasqua S., Guidi C., Terlizzi E., et al. Riluzole and other prognostic factors in ALS: A population-based registry study in Italy. J. Neurol. 2018;265:817&#x2013;827. doi: 10.1007/s00415-018-8778-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8778-y</ArticleId><ArticleId IdType="pubmed">29404735</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasta R., D&#x2019;Ovidio F., Logroscino G., Chi&#xf2; A. The links between diabetes mellitus and amyotrophic lateral sclerosis. Neurol. Sci. 2021;42:1377&#x2013;1387. doi: 10.1007/s10072-021-05099-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05099-0</ArticleId><ArticleId IdType="pmc">PMC7955983</ArticleId><ArticleId IdType="pubmed">33544228</ArticleId></ArticleIdList></Reference><Reference><Citation>Wannarong T., Ungprasert P. Diabetes mellitus is associated with a lower risk of amyotrophic lateral sclerosis: A systematic review and meta-analysis. Clin. Neurol. Neurosurg. 2020;199:106248. doi: 10.1016/j.clineuro.2020.106248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2020.106248</ArticleId><ArticleId IdType="pubmed">33031990</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher J., Peter R.S., Nagel G., Rothenbacher D., Rosenbohm A., Ludolph A.C., Dorst J. The ALS Registry Swabia Study Group Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: Data from 501 patients of a population-based registry in southwest Germany. Eur. J. Neurol. 2020;27:1405&#x2013;1414. doi: 10.1111/ene.14300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14300</ArticleId><ArticleId IdType="pubmed">32396653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellavia A., Dickerson A.S., Rotem R.S., Hansen J., Gredal O., Weisskopf M.G. Joint and interactive effects between health comorbidities and environmental exposures in predicting amyotrophic lateral sclerosis. Int. J. Hyg. Environ. Health. 2021;231:113655. doi: 10.1016/j.ijheh.2020.113655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijheh.2020.113655</ArticleId><ArticleId IdType="pmc">PMC7736520</ArticleId><ArticleId IdType="pubmed">33130429</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefera T.W., Steyn F.J., Ngo S.T., Borges K. CNS glucose metabolism in Amyotrophic Lateral Sclerosis: A therapeutic target? Cell Biosci. 2021;11:1&#x2013;17. doi: 10.1186/s13578-020-00511-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13578-020-00511-2</ArticleId><ArticleId IdType="pmc">PMC7798275</ArticleId><ArticleId IdType="pubmed">33431046</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D., Shamseer L., Clarke M., Ghersi D., Liberati A., Petticrew M., Shekelle P., Stewart L.A., PRISMA-P Group Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 2015;4:1. doi: 10.1186/2046-4053-4-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2046-4053-4-1</ArticleId><ArticleId IdType="pmc">PMC4320440</ArticleId><ArticleId IdType="pubmed">25554246</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D., Hammar N., Malmstr&#xf6;m H., Ingre C., Jungner I., Ye W., Fang F., Walldius G. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort. Ann. Neurol. 2017;81:718&#x2013;728. doi: 10.1002/ana.24936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24936</ArticleId><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell C.S., Hollinger S.K., Goswami S.D., Polak M.A., Lee R.H., Glass J.D. Antecedent Disease Is Less Prevalent in Amyotrophic Lateral Sclerosis. Neurodegener. Dis. 2015;15:109&#x2013;113. doi: 10.1159/000369812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000369812</ArticleId><ArticleId IdType="pmc">PMC4417009</ArticleId><ArticleId IdType="pubmed">25720304</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollinger S.K., Okosun I.S., Mitchell C.S. Antecedent Disease and Amyotrophic Lateral Sclerosis: What Is Protecting Whom? Front. Neurol. 2016;7:47. doi: 10.3389/fneur.2016.00047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2016.00047</ArticleId><ArticleId IdType="pmc">PMC4810157</ArticleId><ArticleId IdType="pubmed">27065942</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai C.-P., Lee J.K.-W., Lee C.T.-C. Type II diabetes mellitus and the incidence of amyotrophic lateral sclerosis. J. Neurol. 2019;266:2233&#x2013;2243. doi: 10.1007/s00415-019-09405-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09405-x</ArticleId><ArticleId IdType="pubmed">31152300</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A., Abid A., Schulz P.E. Diabetes mellitus and amyotrophic lateral sclerosis: Time to bridge the gap between the bench and the bedside. Eur. J. Neurol. 2017;25:3&#x2013;4. doi: 10.1111/ene.13481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13481</ArticleId><ArticleId IdType="pubmed">29044904</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai C.-P., Hu C., Lee C.T.-C. Finding diseases associated with amyotrophic lateral sclerosis: A total population-based case&#x2013;control study. Amyotroph. Lateral Scler. Front. Degener. 2018;20:82&#x2013;89. doi: 10.1080/21678421.2018.1522354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1522354</ArticleId><ArticleId IdType="pubmed">30422689</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S., Kollewe K., Ilsemann J., M&#xfc;ller-Heine A., Dengler R., Krampfl K., Petri S. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur. J. Neurol. 2012;20:647&#x2013;654. doi: 10.1111/ene.12015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12015</ArticleId><ArticleId IdType="pubmed">23094606</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q.-Q., Chen Y., Cao B., Ou R.W., Zhang L., Hou Y., Gao X., Shang H. Blood hemoglobin A1c levels and amyotrophic lateral sclerosis survival. Mol. Neurodegener. 2017;12:69. doi: 10.1186/s13024-017-0211-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0211-y</ArticleId><ArticleId IdType="pmc">PMC5609007</ArticleId><ArticleId IdType="pubmed">28934974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ort&#xed; J.D.L.R., Armero J., Sanchis-Sanchis C., Sancho-Castillo S., Salazar A., Caplliure-Llopis J., Navarro-Illana E., Barrios C., Escrib&#xe1;-Alepuz J., Benlloch M. Muscle Function Differences between Patients with Bulbar and Spinal Onset Amyotrophic Lateral Sclerosis. Does It Depend on Peripheral Glucose? J. Clin. Med. 2021;10:1582. doi: 10.3390/jcm10081582.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10081582</ArticleId><ArticleId IdType="pmc">PMC8069029</ArticleId><ArticleId IdType="pubmed">33918552</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer R.M., Mayer B., Kuncl R.W., Check D.P., Cahoon E.K., Rivera D.R., Freedman D.M. Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs. Amyotroph. Lateral Scler. Front. Degener. 2019;21:235&#x2013;245. doi: 10.1080/21678421.2019.1682613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1682613</ArticleId><ArticleId IdType="pubmed">31684770</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Dengler R., Heneka M.T., Meyer T., Zierz S., Kassubek J., Fischer W., Steiner F., Lindauer E., Otto M., et al. A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis. PLoS ONE. 2012;7:e37885. doi: 10.1371/journal.pone.0037885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037885</ArticleId><ArticleId IdType="pmc">PMC3371007</ArticleId><ArticleId IdType="pubmed">22715372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneb H.M., Sharp P.S., Rahmani-Kondori N., Wells D.J. Metformin Treatment Has No Beneficial Effect in a Dose-Response Survival Study in the SOD1G93A Mouse Model of ALS and Is Harmful in Female Mice. PLoS ONE. 2011;6:e24189. doi: 10.1371/journal.pone.0024189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024189</ArticleId><ArticleId IdType="pmc">PMC3164704</ArticleId><ArticleId IdType="pubmed">21909419</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A., Paganoni S., Hauser C., Schulz P.E. Trials of antidiabetic drugs in amyotrophic lateral sclerosis: Proceed with caution? Neurodegener. Dis. 2013;13:205&#x2013;208. doi: 10.1159/000353158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000353158</ArticleId><ArticleId IdType="pmc">PMC4435550</ArticleId><ArticleId IdType="pubmed">24107404</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A., Coccurello R. What is &#x201c;Hyper&#x201d; in the ALS Hypermetabolism? Mediat. Inflamm. 2017;2017:1&#x2013;11. doi: 10.1155/2017/7821672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/7821672</ArticleId><ArticleId IdType="pmc">PMC5610793</ArticleId><ArticleId IdType="pubmed">29081604</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A., Poon M., Strutt A.M., Rice L.K., McDowell E.J., Salamone A.R., Qureshi S.U., Simpson E., Appel S.H., York M.K., et al. Does apolipoprotein E genotype modify the clinical expression of ALS? Eur. J. Neurol. 2010;18:618&#x2013;624. doi: 10.1111/j.1468-1331.2010.03225.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2010.03225.x</ArticleId><ArticleId IdType="pubmed">20880000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawada T. Type 2 diabetes and amyotrophic lateral sclerosis. Eur. J. Neurol. 2016;23:e9. doi: 10.1111/ene.12893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12893</ArticleId><ArticleId IdType="pubmed">26806221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Canosa A., Gallo S., Cammarosano S., Moglia C., Fuda G., Calvo A., Gabriele M. For the PARALS group ALS clinical trials: Do enrolled patients accurately represent the ALS population? Neurology. 2011;77:1432&#x2013;1437. doi: 10.1212/WNL.0b013e318232ab9b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318232ab9b</ArticleId><ArticleId IdType="pubmed">21956723</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings N.R., Puttaparthi K., Luther C.M., Burns D.K., Elliott J.L. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol. Dis. 2010;40:404&#x2013;414. doi: 10.1016/j.nbd.2010.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.06.017</ArticleId><ArticleId IdType="pubmed">20621187</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings N.R., Puttaparthi K., Dowling K.J., Luther C.M., Burns D.K., Davis K., Elliott J.L. TDP-43, an ALS Linked Protein, Regulates Fat Deposition and Glucose Homeostasis. PLoS ONE. 2013;8:e71793. doi: 10.1371/journal.pone.0071793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0071793</ArticleId><ArticleId IdType="pmc">PMC3742534</ArticleId><ArticleId IdType="pubmed">23967244</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki K., Araki A., Honda D., Izumoto T., Hashizume A., Hijikata Y., Yamada S., Iguchi Y., Hara A., Ikumi K., et al. TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets. J. Clin. Investig. 2019;129:3578&#x2013;3593. doi: 10.1172/JCI124481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI124481</ArticleId><ArticleId IdType="pmc">PMC6715357</ArticleId><ArticleId IdType="pubmed">31355778</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Park K.S., Kim S.H., Yu J., Zhao K., Yu L., Oh K.W., Lee K., Kim J., Chaggar K., et al. IgGs from patients with amyotrophic lateral sclerosis and diabetes target CaV&#x3b1;2&#x3b4;1 subunits impairing islet cell function and survival. Proc. Natl. Acad. Sci. USA. 2019;116:26816&#x2013;26822. doi: 10.1073/pnas.1911956116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1911956116</ArticleId><ArticleId IdType="pmc">PMC6936400</ArticleId><ArticleId IdType="pubmed">31826954</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J., Bury J.J., Heath P.R., Wyles M., Higginbottom A., Gelsthorpe C., Highley J.R., Hautbergue G., Rattray M., Kirby J., et al. C9ORF72 GGGGCC Expanded Repeats Produce Splicing Dysregulation which Correlates with Disease Severity in Amyotrophic Lateral Sclerosis. PLoS ONE. 2015;10:e0127376. doi: 10.1371/journal.pone.0127376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0127376</ArticleId><ArticleId IdType="pmc">PMC4446097</ArticleId><ArticleId IdType="pubmed">26016851</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Wang T., Ji Y.J., Johnson K., Liu H., Johnson K., Bailey S., Suk Y., Lu Y.-N., Liu M., et al. A C9orf72&#x2013;CARM1 axis regulates lipid metabolism under glucose starvation-induced nutrient stress. Genes Dev. 2018;32:1380&#x2013;1397. doi: 10.1101/gad.315564.118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.315564.118</ArticleId><ArticleId IdType="pmc">PMC6217731</ArticleId><ArticleId IdType="pubmed">30366907</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Wang J. C9orf72-dependent lysosomal functions regulate epigenetic control of autophagy and lipid metabolism. Autophagy. 2019;15:913&#x2013;914. doi: 10.1080/15548627.2019.1580106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2019.1580106</ArticleId><ArticleId IdType="pmc">PMC6526819</ArticleId><ArticleId IdType="pubmed">30767689</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab. Res. Rev. 2007;24:14&#x2013;26. doi: 10.1002/dmrr.790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.790</ArticleId><ArticleId IdType="pubmed">17990280</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Beal M.F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2005;191:331&#x2013;336. doi: 10.1016/j.expneurol.2004.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2004.10.007</ArticleId><ArticleId IdType="pubmed">15649489</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N., Kawaguchi-Niida M., Yamamoto T., Toi S., Hirano A., Kobayashi M. Effects of the PPAR&#x3b3; activator pioglitazone on p38 MAP kinase and I&#x3ba;B&#x3b1; in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis. Neuropathology. 2008;28:387&#x2013;398. doi: 10.1111/j.1440-1789.2008.00890.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2008.00890.x</ArticleId><ArticleId IdType="pubmed">18312546</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;tz B., Reimann J., Dumitrescu-Ozimek L., Kappes-Horn K., Landreth G.E., Sch&#xfc;rmann B., Zimmer A., Heneka M.T. The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice. J. Neurosci. 2005;25:7805&#x2013;7812. doi: 10.1523/JNEUROSCI.2038-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2038-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725264</ArticleId><ArticleId IdType="pubmed">16120782</ArticleId></ArticleIdList></Reference><Reference><Citation>Dandona P., Aljada A., Ghanim H., Mohanty P., Tripathy C., Hofmeyer D., Chaudhuri A. Increased Plasma Concentration of Macrophage Migration Inhibitory Factor (MIF) and MIF mRNA in Mononuclear Cells in the Obese and the Suppressive Action of Metformin. J. Clin. Endocrinol. Metab. 2004;89:5043&#x2013;5047. doi: 10.1210/jc.2004-0436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2004-0436</ArticleId><ArticleId IdType="pubmed">15472203</ArticleId></ArticleIdList></Reference><Reference><Citation>Isoda K., Young J.L., Zirlik A., Macfarlane L.A., Tsuboi N., Gerdes N., Sch&#xf6;nbeck U., Libby P. Metformin Inhibits Proinflammatory Responses and Nuclear Factor-&#x3ba;B in Human Vascular Wall Cells. Arter. Thromb. Vasc. Biol. 2006;26:611&#x2013;617. doi: 10.1161/01.ATV.0000201938.78044.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000201938.78044.75</ArticleId><ArticleId IdType="pubmed">16385087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H.Z., Yang S.Q., Chuckaree C., Kuhajda F., Ronnet G., Diehl A.M. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. 2000;6:998&#x2013;1003. doi: 10.1038/79697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/79697</ArticleId><ArticleId IdType="pubmed">10973319</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouslimani N., Peynet J., Bonnefont-Rousselot D., Th&#xe9;rond P., Legrand A., Beaudeux J.-L. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism. 2005;54:829&#x2013;834. doi: 10.1016/j.metabol.2005.01.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2005.01.029</ArticleId><ArticleId IdType="pubmed">15931622</ArticleId></ArticleIdList></Reference><Reference><Citation>Srividhya S., Ravichandran M., Anuradha C. Metformin Attenuates Blood Lipid Peroxidation and Potentiates Antioxidant Defense in High Fructose-fed Rats. J. Biochem. Mol. Biol. Biophys. 2002;6:379&#x2013;385. doi: 10.1080/1025814021000024280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1025814021000024280</ArticleId><ArticleId IdType="pubmed">14972791</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukidome D., Nishikawa T., Sonoda K., Imoto K., Fujisawa K., Yano M., Motoshima H., Taguchi T., Matsumura T., Araki E. Activation of AMP-Activated Protein Kinase Reduces Hyperglycemia-Induced Mitochondrial Reactive Oxygen Species Production and Promotes Mitochondrial Biogenesis in Human Umbilical Vein Endothelial Cells. Diabetes. 2006;55:120&#x2013;127. doi: 10.2337/diabetes.55.01.06.db05-0943.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.55.01.06.db05-0943</ArticleId><ArticleId IdType="pubmed">16380484</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarskis E.J., Berryman S., Vanderleest J.G., Schneider A.R., McClain C.J. Nutritional status of patients with amyotrophic lateral sclerosis: Relation to the proximity of death. Am. J. Clin. Nutr. 1996;63:130&#x2013;137. doi: 10.1093/ajcn/63.1.130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/63.1.130</ArticleId><ArticleId IdType="pubmed">8604660</ArticleId></ArticleIdList></Reference><Reference><Citation>Funalot B., Desport J.-C., Sturtz F., Camu W., Couratier P. High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2009;10:113&#x2013;117. doi: 10.1080/17482960802295192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802295192</ArticleId><ArticleId IdType="pubmed">18792852</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber S.C., Mead R., Shaw P.J. Oxidative stress in ALS: A mechanism of neurodegeneration and a therapeutic target. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2006;1762:1051&#x2013;1067. doi: 10.1016/j.bbadis.2006.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.03.008</ArticleId><ArticleId IdType="pubmed">16713195</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe9;sus P., Fayemendy P., Nicol M., Lautrette G., Sourisseau H., Preux P.-M., Desport J.-C., Marin B., Couratier P. Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 2018;25:97&#x2013;104. doi: 10.1111/ene.13468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13468</ArticleId><ArticleId IdType="pubmed">28940704</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., Lange D.J., Voustianiouk A., MacGrogan D., Ho L., Suh J., Humala N., Thiyagarajan M., Wang J., Pasinetti G.M. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci. 2006;7:29. doi: 10.1186/1471-2202-7-29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-7-29</ArticleId><ArticleId IdType="pmc">PMC1488864</ArticleId><ArticleId IdType="pubmed">16584562</ArticleId></ArticleIdList></Reference><Reference><Citation>Caplliure-Llopis J., Peralta-Chamba T., Carrera-Juli&#xe1; S., Cuerda-Ballester M., Drehmer-Rieger E., L&#xf3;pez-Rodriguez M.M., Ort&#xed; J.E.D.L.R. Therapeutic alternative of the ketogenic Mediterranean diet to improve mitochondrial activity in Amyotrophic Lateral Sclerosis (ALS): A Comprehensive Review. Food Sci. Nutr. 2020;8:23&#x2013;35. doi: 10.1002/fsn3.1324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/fsn3.1324</ArticleId><ArticleId IdType="pmc">PMC6977418</ArticleId><ArticleId IdType="pubmed">31993129</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Wills A.-M. High-Fat and Ketogenic Diets in Amyotrophic Lateral Sclerosis. J. Child Neurol. 2013;28:989&#x2013;992. doi: 10.1177/0883073813488669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0883073813488669</ArticleId><ArticleId IdType="pmc">PMC4438106</ArticleId><ArticleId IdType="pubmed">23666040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyder F., Patel A.B., Gjedde A., Rothman D.L., Behar K., Shulman R.G. Neuronal&#x2013;Glial Glucose Oxidation and Glutamatergic&#x2013;GABAergic Function. Br. J. Pharmacol. 2006;26:865&#x2013;877. doi: 10.1038/sj.jcbfm.9600263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.jcbfm.9600263</ArticleId><ArticleId IdType="pubmed">16407855</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills A.-M., Hubbard J., Macklin E.A., Glass J., Tandan R., Simpson E.P., Brooks B., Gelinas D., Mitsumoto H., Mozaffar T., et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;383:2065&#x2013;2072. doi: 10.1016/S0140-6736(14)60222-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60222-1</ArticleId><ArticleId IdType="pmc">PMC4176708</ArticleId><ArticleId IdType="pubmed">24582471</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., Sui Y., Gao W., Cai B., Fan D. Effects of diet on adenosine monophosphate-activated protein kinase activity and disease progression in an amyotrophic lateral sclerosis model. J. Int. Med. Res. 2015;43:67&#x2013;79. doi: 10.1177/0300060514554725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060514554725</ArticleId><ArticleId IdType="pubmed">25534414</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan K.S., Halang L., Woods I., Prehn J.H.M. A high fat jelly diet restores bioenergetic balance and extends lifespan in the presence of motor dysfunction and lumbar spinal cord motor neuron loss in TDP-43A315T/ C57BL/6J mice. Dis. Model. Mech. 2016;9:1029&#x2013;1037. doi: 10.1242/dmm.024786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.024786</ArticleId><ArticleId IdType="pmc">PMC5047697</ArticleId><ArticleId IdType="pubmed">27491077</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefera T.W., Borges K. Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments. Front. Neurosci. 2017;10:611. doi: 10.3389/fnins.2016.00611.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2016.00611</ArticleId><ArticleId IdType="pmc">PMC5222822</ArticleId><ArticleId IdType="pubmed">28119559</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M., Re D.B., Nagata T., Chalazonitis A., Jessell T.M., Wichterle H., Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007;10:615&#x2013;622. doi: 10.1038/nn1876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1876</ArticleId><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassina P., Cassina A., Pehar M., Castellanos R., Gandelman M., De Le&#xf3;n A., Robinson K.M., Mason R.P., Beckman J.S., Barbeito L., et al. Mitochondrial Dysfunction in SOD1G93A-Bearing Astrocytes Promotes Motor Neuron Degeneration: Prevention by Mitochondrial-Targeted Antioxidants. J. Neurosci. 2008;28:4115&#x2013;4122. doi: 10.1523/JNEUROSCI.5308-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5308-07.2008</ArticleId><ArticleId IdType="pmc">PMC3844766</ArticleId><ArticleId IdType="pubmed">18417691</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Calvo A., Ilardi A., Cavallo E., Moglia C., Mutani R., Palmo A., Galletti R., Marinou K., Papetti L., et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73:1681&#x2013;1685. doi: 10.1212/WNL.0b013e3181c1df1e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df1e</ArticleId><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Calvo A., Moglia C., Mazzini L., Mora G. PARALS study group Phenotypic heterogeneity of amyotrophic lateral sclerosis: A population based study. J. Neurol. Neurosurg. Psychiatry. 2011;82:740&#x2013;746. doi: 10.1136/jnnp.2010.235952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.235952</ArticleId><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Logroscino G., Traynor B., Collins J., Simeone J., Goldstein L., White L. Global Epidemiology of Amyotrophic Lateral Sclerosis: A Systematic Review of the Published Literature. Neuroepidemiology. 2013;41:118&#x2013;130. doi: 10.1159/000351153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923. doi: 10.1126/science.8346443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosentino S., Scarmeas N., Helzner E., Glymour M.M., Brandt J., Albert M., Blacker D., Stern Y. APOE 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology. 2008;70:1842&#x2013;1849. doi: 10.1212/01.wnl.0000304038.37421.cc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000304038.37421.cc</ArticleId><ArticleId IdType="pmc">PMC2676693</ArticleId><ArticleId IdType="pubmed">18401023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiefermeier M., Kollegger H., Madl C., Polli C., Oder W., K&#xfc;hn H.-J., Berr F., Ferenci P. The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson&#x2019;s disease. Brain. 2000;123:585&#x2013;590. doi: 10.1093/brain/123.3.585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/123.3.585</ArticleId><ArticleId IdType="pubmed">10686180</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmenter B.A., Denney D.R., Lynch S.G., Middleton L.S., Harlan L.M. Cognitive impairment in patients with multiple sclerosis: Association with the APOE gene and promoter polymorphisms. Mult. Scler. J. 2007;13:25&#x2013;32. doi: 10.1177/1352458506070682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458506070682</ArticleId><ArticleId IdType="pubmed">17294608</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Everbroeck B., Croes E.A., Pals P., Dermaut B., Jansen G., van Duijn C.M., Cruts M., Van Broeckhoven C., Martin J.-J., Cras P. Influence of the prion protein and the apolipoprotein E genotype on the Creutzfeldt&#x2013;Jakob Disease phenotype. Neurosci. Lett. 2001;313:69&#x2013;72. doi: 10.1016/S0304-3940(01)02264-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)02264-9</ArticleId><ArticleId IdType="pubmed">11684342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza M. Influence of APOE polymorphism on cognitive and behavioural outcome in moderate and severe traumatic brain injury. J. Neurol. Neurosurg. Psychiatry. 2006;77:1191&#x2013;1193. doi: 10.1136/jnnp.2005.085167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.085167</ArticleId><ArticleId IdType="pmc">PMC2077553</ArticleId><ArticleId IdType="pubmed">16614010</ArticleId></ArticleIdList></Reference><Reference><Citation>Louko A.-M., Vilkki J., Niskakangas T. ApoE genotype and cognition after subarachnoid haemorrhage: A longitudinal study. Acta Neurol. Scand. 2006;114:315&#x2013;319. doi: 10.1111/j.1600-0404.2006.00676.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2006.00676.x</ArticleId><ArticleId IdType="pubmed">17022778</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J., Shi J., Bailey K., Lendon C.L., Pickering-Brown S., Mann D.M.A. Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer&#x2019;s disease. J. Neurol. Neurosurg. Psychiatry. 2004;75:696&#x2013;699. doi: 10.1136/jnnp.2003.012096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2003.012096</ArticleId><ArticleId IdType="pmc">PMC1763560</ArticleId><ArticleId IdType="pubmed">15090562</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.J., Hauser M.A., Scott W.K., Martin E.R., Booze M.W., Qin X.J., Walter J.W., Nance M.A., Hubble J.P., Koller W.C., et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004;62:2005&#x2013;2009. doi: 10.1212/01.WNL.0000128089.53030.AC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000128089.53030.AC</ArticleId><ArticleId IdType="pubmed">15184605</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulard B., Sefiani A., Laamri A., Malafosse A., Camu W. Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: Evidence for a major influence on the clinical presentation and prognosis. J. Neurol. Sci. 1996;139:34&#x2013;37. doi: 10.1016/0022-510X(96)00085-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(96)00085-8</ArticleId><ArticleId IdType="pubmed">8899655</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.-J., Pericak-Vance M.A., Haines J.L., Siddique N., McKenna-Yasek D., Hung W.-Y., Sapp P., Allen C.I., Chen W., Hosler B., et al. Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis. Neurogenetics. 2004;5:209&#x2013;213. doi: 10.1007/s10048-004-0193-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-004-0193-0</ArticleId><ArticleId IdType="pubmed">15657798</ArticleId></ArticleIdList></Reference><Reference><Citation>Drory V.E., Birnbaum M., Korczyn A.D., Chapman J. Association of APOE &#x3b5;4 allele with survival in amyotrophic lateral sclerosis. J. Neurol. Sci. 2001;190:17&#x2013;20. doi: 10.1016/S0022-510X(01)00569-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00569-X</ArticleId><ArticleId IdType="pubmed">11574101</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H., Jacobsson J., Rosengren L., Blennow K., Andersen P.M. Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis. J. Neurol. Sci. 2008;273:67&#x2013;69. doi: 10.1016/j.jns.2008.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2008.06.025</ArticleId><ArticleId IdType="pubmed">18656208</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L., Doppler V., Beucler I., Costes G., Salachas F., Raisonnier A., Le Forestier N., Pradat P.-F., Bruckert E., Meininger V. APOE: A potential marker of disease progression in ALS. Neurology. 2002;58:1112&#x2013;1114. doi: 10.1212/WNL.58.7.1112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.7.1112</ArticleId><ArticleId IdType="pubmed">11940705</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichner J.E., Dunn S.T., Perveen G., Thompson D.M., Stewart K.E., Stroehla B.C. Apolipoprotein E Polymorphism and Cardiovascular Disease: A HuGE Review. Am. J. Epidemiol. 2002;155:487&#x2013;495. doi: 10.1093/aje/155.6.487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/155.6.487</ArticleId><ArticleId IdType="pubmed">11882522</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Goldacre R., Ramagopalan S., Talbot K., Goldacre M.J. Autoimmune disease preceding amyotrophic lateral sclerosis: An epidemiologic study. Neurology. 2013;81:1222&#x2013;1225. doi: 10.1212/WNL.0b013e3182a6cc13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a6cc13</ArticleId><ArticleId IdType="pmc">PMC3795611</ArticleId><ArticleId IdType="pubmed">23946298</ArticleId></ArticleIdList></Reference><Reference><Citation>Shieh J.C.-C., Huang P.-T., Lin Y.-F. Alzheimer&#x2019;s Disease and Diabetes: Insulin Signaling as the Bridge Linking Two Pathologies. Mol. Neurobiol. 2020;57:1966&#x2013;1977. doi: 10.1007/s12035-019-01858-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-01858-5</ArticleId><ArticleId IdType="pubmed">31900863</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandimalla R., Thirumala V., Reddy P.H. Is Alzheimer&#x2019;s disease a Type 3 Diabetes? A critical appraisal. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2017;1863:1078&#x2013;1089. doi: 10.1016/j.bbadis.2016.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2016.08.018</ArticleId><ArticleId IdType="pmc">PMC5344773</ArticleId><ArticleId IdType="pubmed">27567931</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;lscher C. Brain insulin resistance: Role in neurodegenerative disease and potential for targeting. Expert Opin. Investig. Drugs. 2020;29:333&#x2013;348. doi: 10.1080/13543784.2020.1738383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2020.1738383</ArticleId><ArticleId IdType="pubmed">32175781</ArticleId></ArticleIdList></Reference><Reference><Citation>De La Monte S.M. Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer&#x2019;s Disease. Drugs. 2017;77:47&#x2013;65. doi: 10.1007/s40265-016-0674-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-016-0674-0</ArticleId><ArticleId IdType="pmc">PMC5575843</ArticleId><ArticleId IdType="pubmed">27988872</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>